Management of Anticoagulant Therapy in Athletes and Sportspeople: Italian Federation of Centers for Diagnosis and Surveillance of the Antithrombotic Therapies (FCSA) Position Paper

Abstract

This position paper offers expert guidance on managing anticoagulant therapy in athletes and sportspeople, addressing the unique challenges posed by the dual need for effective thromboprophylaxis and maintenance of athletic performance. Recognizing that conditions such as atrial fibrillation and venous thromboembolism occur with higher prevalence in athletes due to factors like intense physical training, dehydration, trauma, and long-haul travel, the paper reviews current literature and expert opinions from the Italian Federation of Centers for Diagnosis and Surveillance of the Antithrombotic Therapies. The manuscript highlights that although direct oral anticoagulants (DOACs) are generally preferred for their favorable efficacy and safety profile compared with traditional vitamin K antagonists (VKAs), their use in sports demands careful risk stratification. To balance effective anticoagulation with the risk of bleeding, individualized treatment strategies—including intermittent dosing regimens with DOACs—are suggested. These strategies aim to minimize bleeding risk during periods of high physical demand while preserving therapeutic effectiveness. In athletes requiring VKA therapy, sport participation—especially contact or high-impact activities—should be strongly discouraged due to the inability to manage bleeding and thrombotic risks safely. Moreover, the paper emphasizes the importance of periodic re-assessment of thromboembolic and hemorrhagic risks, multidisciplinary collaboration among cardiologists, hematologists, and sports medicine specialists, and shared decision-making with the athlete. By offering practical suggestions on treatment modifications, return-to-play protocols, and patient education, this position paper serves as a critical resource for clinicians striving to optimize anticoagulant therapy in athletic populations without compromising competitive performance.

Keywords

venous thromboembolism - atrial fibrillation - sport medicine - trauma - bleeding

Publikationsverlauf

Eingereicht: 07. April 2025

Angenommen: 10. Juni 2025

Accepted Manuscript online:
11. Juni 2025

Artikel online veröffentlicht:
24. Juni 2025

• References

• 1 Kichloo A, Amir R, Wani F, Randhawa S, Rudd B, Rechlin D. Anticoagulation and antiplatelet therapy in contact sports: is it career limiting?. J Investig Med 2021; 69 (03) 781-784
• 2 Furlanello F, Bertoldi A, Dallago M. et al. Atrial fibrillation in elite athletes. J Cardiovasc Electrophysiol 1998; 9 (8, Suppl): S63-S68
• 3 Grimsmo J, Grundvold I, Maehlum S, Arnesen H. High prevalence of atrial fibrillation in long-term endurance cross-country skiers: echocardiographic findings and possible predictors—a 28-30 years follow-up study. Eur J Cardiovasc Prev Rehabil 2010; 17 (01) 100-105
• 4 Koopman P, Nuyens D, Garweg C. et al. Efficacy of radiofrequency catheter ablation in athletes with atrial fibrillation. Europace 2011; 13 (10) 1386-1393
• 5 Zipes DP, Link MS, Ackerman MJ, Kovacs RJ, Myerburg RJ, Estes III NAM. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 9: Arrhythmias and conduction defects. J Am Coll Cardiol 2015; 66 (21) 2412-2423
• 6 Bishop M, Astolfi M, Padegimas E, DeLuca P, Hammoud S. Venous thromboembolism within professional American sport leagues. Orthop J Sports Med 2017; 5 (12) 2325967117745530
• 7 Eichner ER. Blood clots and plane flights. Curr Sports Med Rep 2009; 8 (03) 106-107
• 8 Ferrari E, Chevallier T, Chapelier A, Baudouy M. Travel as a risk factor for venous thromboembolic disease: a case-control study. Chest 1999; 115 (02) 440-444
• 9 Parker B, Augeri A, Capizzi J. et al. Effect of air travel on exercise-induced coagulatory and fibrinolytic activation in marathon runners. Clin J Sport Med 2011; 21 (02) 126-130
• 10 Hull CM, Harris JA. Venous thromboembolism in physically active people: considerations for risk assessment, mainstream awareness and future research. Sports Med 2015; 45 (10) 1365-1372
• 11 Rice SG. American Academy of Pediatrics Council on Sports Medicine and Fitness. Medical conditions affecting sports participation. Pediatrics 2008; 121 (04) 841-848
• 12 Montalvo AM, Schneider DK, Webster KE. et al. Anterior cruciate ligament injury risk in sport: a systematic review and meta-analysis of injury incidence by sex and sport classification. J Athl Train 2019; 54 (05) 472-482
• 13 Araújo CG, Scharhag J. Athlete: a working definition for medical and health sciences research. Scand J Med Sci Sports 2016; 26 (01) 4-7
• 14 Van Gelder IC, Rienstra M, Bunting KV. et al; ESC Scientific Document Group. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2024; 45 (36) 3314-3414
• 15 Go AS, Hylek EM, Phillips KA. et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285 (18) 2370-2375
• 16 Pelliccia A, Maron BJ, Di Paolo FM. et al. Prevalence and clinical significance of left atrial remodeling in competitive athletes. J Am Coll Cardiol 2005; 46 (04) 690-696
• 17 Wernhart S, Halle M. Atrial fibrillation and long-term sports practice: epidemiology and mechanisms. Clin Res Cardiol 2015; 104 (05) 369-379
• 18 Calvo N, Ramos P, Montserrat S. et al. Emerging risk factors and the dose-response relationship between physical activity and lone atrial fibrillation: a prospective case-control study. Europace 2016; 18 (01) 57-63
• 19 Sanchis-Gomar F, Perez-Quilis C, Lippi G. et al. Atrial fibrillation in highly trained endurance athletes—description of a syndrome. Int J Cardiol 2017; 226: 11-20
• 20 Sharma S. Reloaded: Searching for the perfect dose of exercise? In: Proceedings of the Davos Congress. Davos, Switzerland, January 23–26, 2018
• 21 Newman W, Parry-Williams G, Wiles J. et al. Risk of atrial fibrillation in athletes: a systematic review and meta-analysis. Br J Sports Med 2021; 55 (21) 1233-1238
• 22 Aizer A, Gaziano JM, Cook NR, Manson JE, Buring JE, Albert CM. Relation of vigorous exercise to risk of atrial fibrillation. Am J Cardiol 2009; 103 (11) 1572-1577
• 23 Andersen K, Farahmand B, Ahlbom A. et al. Risk of arrhythmias in 52 755 long-distance cross-country skiers: a cohort study. Eur Heart J 2013; 34 (47) 3624-3631
• 24 La Gerche A, Schmied CM. Atrial fibrillation in athletes and the interplay between exercise and health. Eur Heart J 2013; 34 (47) 3599-3602
• 25 Morseth B, Graff-Iversen S, Jacobsen BK. et al. Physical activity, resting heart rate, and atrial fibrillation: the Tromsø Study. Eur Heart J 2016; 37 (29) 2307-2313
• 26 Sciarra L, Cavarretta E, Siciliani S. et al. Managing athletes with palpitations of unknown origin with an external loop recorder: a cohort study. J Sports Med Phys Fitness 2022; 62 (04) 554-559
• 27 Petrungaro M, Fusco L, Cavarretta E. et al. Long-term sports practice and atrial fibrillation: an updated review of a complex relationship. J Cardiovasc Dev Dis 2023; 10 (05) 218
• 28 Minardi S, Sciarra L, Robles AG. et al. Thromboembolic prevention in athletes: management of anticoagulation in sports players affected by atrial fibrillation. Front Pharmacol 2024; 15: 1384213
• 29 Sanna GD, Gabrielli E, De Vito E, Nusdeo G, Prisco D, Parodi G. Atrial fibrillation in athletes: from epidemiology to treatment in the novel oral anticoagulants era. J Cardiol 2018; 72 (04) 269-276
• 30 Kunutsor SK, Mäkikallio TH, Seidu S. et al. Physical activity and risk of venous thromboembolism: systematic review and meta-analysis of prospective cohort studies. Eur J Epidemiol 2020; 35 (05) 431-442
• 31 Evensen LH, Brækkan SK, Hansen JB. Regular physical activity and risk of venous thromboembolism. Semin Thromb Hemost 2018; 44 (08) 765-779
• 32 Swan D, Carter-Brzezinski L, Thachil J. Management of venous thromboembolism in athletes. Blood Rev 2021; 47: 100780
• 33 Posthuma JJ, van der Meijden PEJ, Ten Cate H, Spronk HMH. Short- and long-term exercise induced alterations in haemostasis: a review of the literature. Blood Rev 2015; 29 (03) 171-178
• 34 El-Sayed MS, El-Sayed Ali Z, Ahmadizad S. Exercise and training effects on blood haemostasis in health and disease: an update. Sports Med 2004; 34 (03) 181-200
• 35 Kicken CH, Miszta A, Kelchtermans H, De Laat B. Hemostasis during extreme exertion. Semin Thromb Hemost 2018; 44 (07) 640-650
• 36 Zadow EK, Adams MJ, Kitic CM, Wu SSX, Fell JW. Acquired and genetic thrombotic risk factors in the athlete. Semin Thromb Hemost 2018; 44 (08) 723-733
• 37 Hirokawa M, Iwai T, Inoue Y, Sato S. Surgical treatment of popliteal vein entrapment causing symptoms. Phlebology 2002; 17 (3-4) 103-107
• 38 Leon M, Volteas N, Labropoulos N. et al. Popliteal vein entrapment in the normal population. Eur J Vasc Surg 1992; 6 (06) 623-627
• 39 Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Old and new risk factors for upper extremity deep venous thrombosis. J Thromb Haemost 2005; 3 (11) 2471-2478
• 40 Shebel ND, Marin A. Effort thrombosis (Paget-Schroetter syndrome) in active young adults: current concepts in diagnosis and treatment. J Vasc Nurs 2006; 24 (04) 116-126
• 41 May R, Thurner J. The cause of the predominantly sinistral occurrence of thrombosis of the pelvic veins. Angiology 1957; 8 (05) 419-427
• 42 Perry M, Kemmis Betty S, Downes N, Andrews N, Mackenzie S. Atrial fibrillation: diagnosis and management—summary of NICE guidance. BMJ 2021 373:n1150
• 43 Andrade JG, Aguilar M, Atzema C. et al; Members of the Secondary Panel. The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the management of atrial fibrillation. Can J Cardiol 2020; 36 (12) 1847-1948
• 44 Buka RJ. Andexanet alfa: trials just leave us with more questions. Res Pract Thromb Haemost 2024; 9 (01) 102628
• 45 Simioni P, Cipriano A, D'Angelo A. et al. The efficacy and safety of andexanet alfa in the treatment of anticoagulation-related major bleedings: an Italian perspective. Thromb Res 2025; 245: 109241
• 46 Lampert R, Chung EH, Ackerman MJ. et al. 2024 HRS expert consensus statement on arrhythmias in the athlete: evaluation, treatment, and return to play. Heart Rhythm 2024; 21 (10) e151-e252
• 47 Heidbüchel H, Panhuyzen-Goedkoop N, Corrado D. et al; Study Group on Sports Cardiology of the European Association for Cardiovascular Prevention and Rehabilitation. Recommendations for participation in leisure-time physical activity and competitive sports in patients with arrhythmias and potentially arrhythmogenic conditions Part I: Supraventricular arrhythmias and pacemakers. Eur J Cardiovasc Prev Rehabil 2006; 13 (04) 475-484
• 48 Sharma S, Pelliccia A, Gati S. The “Ten Commandments” for the 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J 2021; 42 (01) 6-7
• 49 Maron BJ, Zipes DP, Kovacs RJ. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: preamble, principles, and general considerations. J Am Coll Cardiol 2015; 66 (21) 2343-2349
• 50 Zeppilli P, Biffi A, Cammarano M. et al. Italian Cardiological Guidelines (COCIS) for Competitive Sport Eligibility in athletes with heart disease: update 2024. Minerva Med 2024; 115 (05) 533-564
• 51 Thelle DS, Selmer R, Gjesdal K. et al. Resting heart rate and physical activity as risk factors for lone atrial fibrillation: a prospective study of 309,540 men and women. Heart 2013; 99 (23) 1755-1760
• 52 Nazha B, Pandya B, Spyropoulos AC, Kessler CM. Treatment of venous thromboembolism in elite athletes: a suggested approach to individualized anticoagulation. Semin Thromb Hemost 2018; 44 (08) 813-822
• 53 Palareti G, Legnani C, Cosmi B, Guazzaloca G, Cini M, Mattarozzi S. Poor anticoagulation quality in the first 3 months after unprovoked venous thromboembolism is a risk factor for long-term recurrence. J Thromb Haemost 2005; 3 (05) 955-961
• 54 Kearon C, Akl EA, Ornelas J. et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016; 149 (02) 315-352
• 55 Ortel TL, Neumann I, Ageno W. et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv 2020; 4 (19) 4693-4738
• 56 Middeldorp S, Nieuwlaat R, Baumann Kreuziger L. et al. American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing. Blood Adv 2023; 7 (22) 7101-7138
• 57 Weitz JI, Lensing AWA, Prins MH. et al; EINSTEIN CHOICE Investigators. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med 2017; 376 (13) 1211-1222
• 58 Agnelli G, Buller HR, Cohen A. et al; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369 (09) 799-808
• 59 Moll S, Berkowitz JN, Miars CW. Elite athletes and anticoagulant therapy: an intermittent dosing strategy. Hematology Am Soc Hematol Educ Program 2018; 2018 (01) 412-417
• 60 Douketis JD, Spyropoulos AC, Duncan J. et al. Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant. JAMA Intern Med 2019; 179 (11) 1469-1478
• 61 Prandoni P, Noventa F, Ghirarduzzi A. et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 2007; 92 (02) 199-205
• 62 Carrier M, Le Gal G, Wells PS, Rodger MA. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med 2010; 152 (09) 578-589
• 63 Testa S, Tripodi A, Legnani C. et al; START-Laboratory Register. Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: results observed in four anticoagulation clinics. Thromb Res 2016; 137: 178-183
• 64 Testa S, Paoletti O, Legnani C. et al. Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants. J Thromb Haemost 2018; 16 (05) 842-848
• 65 Squizzato A, Poli D, Barcellona D. et al; Scientific Reviewer Committee. Management of DOAC in patients undergoing planned surgery or invasive procedure: Italian Federation of Centers for the Diagnosis of Thrombotic Disorders and the Surveillance of the Antithrombotic Therapies (FCSA) Position Paper. Thromb Haemost 2022; 122 (03) 329-335
• 66 Brennan Jr FH. Diagnosis, management of, and return to play guidance for venous thromboembolism in athletes. Curr Sports Med Rep 2022; 21 (04) 129-136
• 67 Depenbrock PJ. Thromboembolic disorders: guidance for return-to-play. Curr Sports Med Rep 2011; 10 (02) 78-83
• 68 Roberts WO, Christie Jr DM. Return to training and competition after deep venous calf thrombosis. Med Sci Sports Exerc 1992; 24 (01) 2-5
• 69 Grabowski G, Whiteside WK, Kanwisher M. Venous thrombosis in athletes. J Am Acad Orthop Surg 2013; 21 (02) 108-117
• 70 Campello E, Bucciarelli P, Catalani F, Erba N, Squizzato A, Poli D. Scientific Reviewer Committee. Anticoagulant therapy in pregnant women with mechanical heart valves: Italian Federation of Centers for Diagnosis and Surveillance of the Antithrombotic Therapies (FCSA) Position Paper. Thromb Haemost 2024; 124 (08) 695-708
• 71 Monagle P, Cuello CA, Augustine C. et al. American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism. Blood Adv 2018; 2 (22) 3292-3316
• 72 Witmer C, Raffini L. Treatment of venous thromboembolism in pediatric patients. Blood 2020; 135 (05) 335-343
• 73 Bastas D, Brandão LR, Vincelli J, Schneiderman JE, Cunningham J, Avila ML. Physical activity for children with deep vein thrombosis and pulmonary embolism on anticoagulation: a scoping review. Res Pract Thromb Haemost 2023; 7 (02) 100094
• 74 Bosch A, Olivieri M, Holzhauer S. The use of DOACs in pediatrics: current therapeutic and prophylactic indications, cardiac indications, and real-world evidence—a review. Hamostaseologie 2025; 45 (01) 89-101
• 75 Male C, Lensing AWA, Palumbo JS. et al; EINSTEIN-Jr Phase 3 Investigators. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematol 2020; 7 (01) e18-e27
• 76 Young G, Lensing AWA, Monagle P. et al; EINSTEIN-Jr. Phase 3 Investigators. Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein-Jr phase 3 dose-exposure-response evaluation. J Thromb Haemost 2020; 18 (07) 1672-1685
• 77 Chao TF, Liu CJ, Wang KL. et al. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation?. J Am Coll Cardiol 2015; 65 (07) 635-642